Antibody-targeted thrombolytic agents
Related Experiment Video
Updated: Sep 19, 2026

Prehospital Thrombolysis: A Manual from Berlin
Published on: November 26, 2013
E Haber1, T Quertermous, G R Matsueda
1Cardiac Unit, Massachusetts General Hospital, Boston 02114.
Abstract:
Plasminogen activator therapy for acute myocardial infarction has become standard medical practice. Bleeding complications, however, limit the utility of the currently available agents. This article reviews how the tools of immunology, molecular biology and protein engineering are being used to develop safer and more effective plasminogen activators.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Antibody Actions
Neutralization
Antibodies can bind to pathogens, preventing them from infecting host cells. This process...
Venous Thrombosis III: Interprofessional Care

